Last updated: October 16, 2024
Sponsor: Lo.Li.Pharma s.r.l
Overall Status: Active - Recruiting
Phase
N/A
Condition
Polycystic Ovarian Syndrome
Reproductive Health
Treatment
Diosgenin
Clinical Study ID
NCT06639698
PILOT-PHD-129
Ages 18-45 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosis of PCOS of phenotype D, according to the Rotterdam Criteria and theEGOI-PCOS Criteria
Exclusion
Exclusion Criteria:
Diagnosis of PCOS of phenotype A, B or C, according to the Rotterdam Criteria andthe EGOI-PCOS Criteria
Hormonal treatments;
Treatments with inositol or other insulin sensitizers (such as metformin);
Insulin resistance or pre-diabetes condition
BMI > 30
Endocrinological alterations
Chronic pharmacological therapies
Major pathological conditions (e.g. tumors or autoimmune diseases)
Study Design
Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Diosgenin
Phase:
Study Start date:
October 14, 2024
Estimated Completion Date:
June 30, 2025
Connect with a study center
Alma Res Fertility Center
Rome, ITA 00198
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.